Literature DB >> 12454271

Evidence for vesicles that mediate long-chain fatty acid uptake by human microvascular endothelial cells.

Axel Ring1, Jürgen Pohl, Alfred Völkl, Wolfgang Stremmel.   

Abstract

This study analyzes the mechanisms of long-chain fatty acid (LCFA) uptake by human microvascular endothelial cells (HMEC). The time course revealed the presence of an early, carrier-mediated uptake component and a later component mediated by clathrin-coated vesicles (CCV) and caveolae, as evidenced by three different experimental approaches: 1) significant reduction of [3H]oleate uptake over 5 min by either inhibition of CCV formation by potassium depletion or hypertonic medium, or disruption of caveolae by filipin III or cyclodextrin. 2) Co-localization of intracellular 12-(N-methyl)-N-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]octadecanoic acid with CCV and caveolae using confocal laser scanning microscopy. 3) Enrichment of [3H]oleate in a subcellular fraction containing CCV and caveolae. Within 10 min, more than 75% of intracellular [3H]oleate remained unmetabolized, suggesting that HMEC preferentially shuttle LCFA through the cell using CCV and caveolae as carriers. The uptake of albumin paralleled that of oleate within the first 10 min, suggesting internalization of at least some LCFA bound to albumin. Compared to oleate and albumin, the uptake of sucrose and dextran was low, indicating a potential minor contribution of fluid-phase endocytosis to the total vesicular LCFA uptake. The data indicate a previously unrecognized role of both CCV and caveolae for the uptake of LCFA by HMEC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454271     DOI: 10.1194/jlr.m200285-jlr200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

1.  The effect of caveolin-1 (Cav-1) on fatty acid uptake and CD36 localization and lipotoxicity in vascular smooth muscle (VSM) cells.

Authors:  Heather M Mattern; Leena S Raikar; Christopher D Hardin
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2008-11-20

2.  FAT/CD36-mediated long-chain fatty acid uptake in adipocytes requires plasma membrane rafts.

Authors:  Jürgen Pohl; Axel Ring; Umine Korkmaz; Robert Ehehalt; Wolfgang Stremmel
Journal:  Mol Biol Cell       Date:  2004-10-20       Impact factor: 4.138

3.  Mathematical Models Suggest Facilitated Fatty Acids Crossing of the Luminal Membrane in the Cardiac Muscle.

Authors:  Efrath Barta
Journal:  J Membr Biol       Date:  2016-12-03       Impact factor: 1.843

4.  Internalization of hydroxyapatite nanoparticles in liver cancer cells.

Authors:  Ingo Werner Bauer; Shi-Pu Li; Ying-Chao Han; Lin Yuan; Mei-Zhen Yin
Journal:  J Mater Sci Mater Med       Date:  2007-08-15       Impact factor: 3.896

5.  Subcellular immunolocalisation of fatty acid translocase (FAT)/CD36 in human type-1 and type-2 skeletal muscle fibres.

Authors:  Hans A Keizer; Gert Schaart; Narenda N Tandon; Jan F C Glatz; Joost J F P Luiken
Journal:  Histochem Cell Biol       Date:  2004-01-23       Impact factor: 4.304

Review 6.  CD36 actions in the heart: Lipids, calcium, inflammation, repair and more?

Authors:  Nada A Abumrad; Ira J Goldberg
Journal:  Biochim Biophys Acta       Date:  2016-03-21

7.  In silico models for dynamic connected cell cultures mimicking hepatocyte-endothelial cell-adipocyte interaction circle.

Authors:  Chiara Andreoni; Gianni Orsi; Carmelo De Maria; Francesca Montemurro; Giovanni Vozzi
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

8.  Uptake of long chain fatty acids is regulated by dynamic interaction of FAT/CD36 with cholesterol/sphingolipid enriched microdomains (lipid rafts).

Authors:  Robert Ehehalt; Richard Sparla; Hasan Kulaksiz; Thomas Herrmann; Joachim Füllekrug; Wolfgang Stremmel
Journal:  BMC Cell Biol       Date:  2008-08-13       Impact factor: 4.241

Review 9.  Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update.

Authors:  Natalie L Trevaskis; William N Charman; Christopher J H Porter
Journal:  Adv Drug Deliv Rev       Date:  2007-11-07       Impact factor: 15.470

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.